References
Maynard A, Bloor K. Regulating the pharmaceutical industry. BMJ 1997; 315: 200–1
Steinbrook R. Registration of clinical trials: voluntary or mandatory?. N Engl J Med 2004; 351 (18): 1820–2
Abbasi K. Editor’s choice. BMJ 2005, 330
Williams M. An inquiry by the UK House of Commons Select Committee into the influence of the pharmaceutical industry [online]. Available frm URL: http://www.meactionuk.org.uk/ HoC Select Ctte_Inquiry into Pharma.htm [Accessed 2005 Apr 28]
Miners AH, Garau M, Fidan D, et al. Comparing estimates of cost effectiveness submitted to the National Institute of Clinical Excellence (NICE) by different organisations: a retrospective study. BMJ 2005; 330: 65–8
Maynard A, Bloor K, Freemantle N. Challenges for the National Institute of Clinical Excellence. BMJ 2004; 329: 327–9
Acknowledgements
Alan Maynard is Chair of York NHS Hospitals Trust. No industry or government funding has been used in the preparation of this editorial.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maynard, A. Quality control in the regulation of pharmaceuticals. Pharmacoeconomics 23, 421–422 (2005). https://doi.org/10.2165/00019053-200523050-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200523050-00001